Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 263

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 263
---
 106,982 and 71,628 shares as of December 31, 2023, and December 31, 2022, respectively; As of December 31, 2023 and 2022, aggregate liquidation preference of $3,809 and $2,723, respectively |     |      |    |     |                    |   3,809 |   |     |                    |   2,723 |   |
| Total temporary equity                                                                                                                                                                                                                                                                                  |     |      |    |     |                    |  35,098 |   |     |                    |  34,012 |   |
| Shareholders’ deficit:                                                                                                                                                                                                                                                                                  |     |      |    |     |                    |         |   |     |                    |         |   |
| Ordinary shares, NIS 0.01 par value; Authorized: 1,870,991 shares; issued and outstanding: 64,879 shares                                                                                                                                                                                                |     |      | 11 |     |                    |      (* | ) |     |                    |      (* | ) |
| Additional paid-in capital                                                                                                                                                                                                                                                                              |     |      |    |     |                    |   1,042 |   |     |                    |     754 |   |
| Accumulated deficit                                                                                                                                                                                                                                                                                     |     |      |    |     |                    | -46,947 |   |     |                    | (42,815 | ) |
| Total shareholders’ deficit                                                                                                                                                                                                                                                                             |     |      |    |     |                    | (45,905 | ) |     |                    | (42,061 | ) |
| Total liabilities, temporary equity and shareholders’ deficit                                                                                                                                                                                                                                           |     |      |    |     | $                  |     360 |   |     | $                  |   1,717 |   |

| (*) | Represents          
 amount less than $1 |

<div align='center'>The accompanying notes are an integral part of
the financial statements.

F-18</div>

REGENTIS BIOMATERIALS LTD.

STATEMENTS OF COMPREHENSIVE LOSS

U.S. dollars in thousands (except share and per share data)

|                                                                                          |     | Note |     | For the Year Ended 
 December 31,       
 2023               |        |   |     | 2022 |        |   |
|:-----------------------------------------------------------------------------------------|:----|:-----|:----|:-------------------|-------:|:--|:----|:-----